Serum triglycerides predict first cardiovascular events in diabetic patients with hypercholesterolemia and retinopathy

European Journal of Preventive Cardiology

Volumn 25, Issue 17, 2018, Pages 1852-1860

  Tada, Hayato ^a   Kawashiri, Masa aki ^a   Nomura, Akihiro ^a,b   Yoshimura, Kenichi ^b   Itoh, Hiroshi ^c   Komuro, Issei ^d   Yamagishi, Masakazu ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

Cardiovascular disease; Residual risk; Statin; Triglycerides

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; BODY MASS; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DIABETIC RETINOPATHY; DOUBLE BLIND PROCEDURE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR ADVERSE CARDIAC EVENT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL; UNSTABLE ANGINA PECTORIS; BLOOD; CLINICAL TRIAL; FEMALE; JAPAN; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; TIME FACTOR;

AGED; BIOMARKERS; CARDIOVASCULAR DISEASES; DIABETIC RETINOPATHY; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; JAPAN; MALE; MIDDLE AGED; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TRIGLYCERIDES;

EID: 85053420567     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/2047487318796989     Document Type: Article

References (30)

1. Kannel WB. Lipids, diabetes, and coronary heart disease: Insights from the Framingham Study. Am Heart J 1985; 110: 1100-1107.
2. Xie J, Ikram MK, Cotch MF, et al. Association of diabetic macular edema and proliferative diabetic retinopathy with cardiovascular disease: A systematic review and meta-analysis. JAMA Ophthalmol 2017; 135: 586-593.
3. Teramoto T, Sasaki J, Ishibashi S, et al. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan-2012 version. J Atheroscler Thromb 2014; 21: 296-298.
4. Catapano AL, Graham I, De Backer G, et al. 2016 ESC/ EAS guidelines for the management of dyslipidaemias. Eur Heart J 2016; 37: 2999-3058.
5. Ueshima K, Itoh H, Kanazawa N, et al. Rationale and design of the standard versus intensive statin therapy for hypercholesterolemic patients with diabetic retinopathy (EMPATHY) study: A randomized controlled trial. J Atheroscler Thromb 2016; 23: 976-990.
6. Itoh H, Komuro I, Takeuchi M, et al. Intensive treat-totarget statin therapy in high-risk Japanese patients with hypercholesterolaemia and diabetic retinopathy: Report of a randomised study. Diabetes Care 2018; 41: 1275-1284.
7. Collins R, Armitage J, Parish S, et al.; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet 2003; 361: 2005-2016.
8. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-696.
9. Reith C and Armitage J. Management of residual risk after statin therapy. Atherosclerosis 2016; 245: 161-170.
10. Austin MA, Rodriguez BL, McKnight B, et al. Low-density lipoprotein particle size, triglycerides, and high-density lipoprotein cholesterol as risk factors for coronary heart disease in older Japanese-American men. Am J Cardiol 2000; 86: 412-416.
11. Sharrett AR, Ballantyne CM, Coady SA, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001; 104: 1108-1113.
12. Miller M, Cannon CP, Murphy SA, et al. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2008; 51: 724-730.
13. Schwartz GG, Abt M, Bao W, et al. Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins. J Am Coll Cardiol 2015; 65: 2267-2275.
14. DeLong ER, DeLong DM and Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics 1988; 44: 837-845.
15. Ferrari R, Aguiar C, Alegria E, et al. Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. Eur Heart J Suppl 2016; 18: C2-C12.
16. Reiner Ž. Hypertriglyceridaemia and risk of coronary artery disease. Nat Rev Cardiol 2017; 14: 401-411.
17. Reiner Z. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: A clinical update. Nutr Metab Cardiovasc Dis 2013; 23: 799-807.
18. Sacks FM, Hermans MP, Fioretto P, et al. Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: A global case-control study in 13 countries. Circulation 2014; 129: 999-1008.
19. Tada H, Kawashiri MA, Nohara A, et al. Lipid management in a Japanese community: Attainment rate of target set by the Japan Atherosclerosis Society Guidelines for the prevention of atherosclerotic cardiovascular diseases 2012. J Atheroscler Thromb 2017; 24: 338-345.
20. Faergeman O, Holme I, Fayyad R, et al. Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease. Am J Cardiol 2009; 104: 459-463.
21. Do R, Willer CJ, Schmidt EM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet 2013; 45: 1345-1352.
22. Liu DJ, Peloso GM, Yu H, et al. Exome-wide association study of plasma lipids in > 300,000 individuals. Nat Genet 2017; 49: 1758-1766.
23. Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis. Lancet 2007; 369: 1090-1098.
24. Elam MB, Ginsberg HN, Lovato LC, et al. Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes. JAMA Cardiol 2017; 2: 370-380.
25. Kubota Y, Iso H, Yamagishi K, et al.; JPHC Study Group. Daily total physical activity and incident stroke: The Japan public health center-based prospective study. Stroke 2017; 48: 1730-1736.
26. Bonaventure A, Kurth T, Pico F, et al. Triglycerides and risk of hemorrhagic stroke vs. ischemic vascular events: The Three-City Study. Atherosclerosis 2010; 210: 243-248.
27. Wieberdink RG, Poels MM, Vernooij MW, et al. Serum lipid levels and the risk of intracerebral hemorrhage: The Rotterdam Study. Arterioscler Thromb Vasc Biol 2011; 31: 2982-2989.
28. Kramer CK, Rodrigues TC, Canani LH, et al. Diabetic retinopathy predicts all-cause mortality and cardiovascular events in both type 1 and 2 diabetes: Meta-analysis of observational studies. Diabetes Care 2011; 34: 1238-1244.
29. Nordestgaard BG, Benn M, Schnohr P, et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007; 298: 299-308.
30. Nordestgaard BG, Langsted A, Mora S, et al. Fasting is not routinely required for determination of a lipid profile: Clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J 2016; 37: 1944-1958.